Results 161 to 170 of about 11,256 (207)

Clinical prognostic value of homologous recombination repair axis markers and PARP1 expression in breast cancer: a systematic review, meta-analysis, and independent cohort validation. [PDF]

BMC Cancer
Shen K, Cai L, Wu W.
europepmc   +1 more source

Temozolomide and olaparib for the treatment of an ARID1A-mutated uterine carcinosarcoma: A case report. [PDF]

Gynecol Oncol Rep
Liu C, Abozenah Y, Rutherford TJ, Andikyan V, Kohut A, Anderson ML.   +5 more
europepmc   +1 more source

Oxidative stress triggers RNAPII arrest through PARylation and DNA damage. [PDF]

Nat Commun
Thomas QA, Wu L, Lesage E, Iversen HKM, López Martínez D, Kompocholi S, Liu H, Nieto Moreno N, Gregersen LH.   +8 more
europepmc   +1 more source

A 5-Azetidinyl BODIPY-Olaparib Conjugate for PARP-Targeted Nuclear and Orthotopic Oral Tumor Imaging. [PDF]

ChemMedChem
Yan K, Qi H, Dong X, Zhao W.
europepmc   +1 more source

A Novel BRCA1 Pathogenic Variant in Tunisian Patient With High Grade Ovarian Cancer: Favorable Therapeutic Response to Olaparib. [PDF]

Cancer Rep (Hoboken)
Ammous-Boukhris N, Abdelmaksoud-Dammak R, Feki A, Khemiri S, Charfi S, Sallemi-Boudawara T, Daoud J, Khanfir A, Gargouri RM.   +8 more
europepmc   +1 more source

PARP Inhibitors as Radiosensitizers: Current Evidence and Future Directions. [PDF]

Curr Oncol Rep
Pereira E, Pereira F, Campos G, Abrantes AM, Botelho MF, Silva-Vaz P, Pires AS.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Overcoming PARPi Resistance: Preclinical and Clinical Evidence in Ovarian Cancer

Drug Resistance Updates, 2021
Ovarian cancer is the fifth cause of cancer-related deaths in women with high grade serous carcinoma (HGSOC) representing the most common histological subtype. Approximately 50 % of HGSOC are characterized by deficiency in homologous recombination (HR), one of the main cellular pathways to repair DNA double strand breaks and one of the well-described ...
Francesco Bertoni, Federica Guffanti, Giovanna Damià   +2 more
exaly   +3 more sources

PARPis and Other Novel, Targeted Therapeutics in Pancreatic Adenocarcinoma

Hematology/Oncology Clinics of North America, 2022
Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with a mere ∼10% of patients in the United States surviving 5 years from the time of diagnosis. Until recently, the treatment for advanced PDAC differed little based on patient or tumor characteristics.
William J, Chapin, Kim A, Reiss
openaire   +2 more sources